Regular ophthalmologic examination to monitor progression of CHM is recommended as affected individuals need advice regarding their levels of visual function. Goldmann visual field examinations provide practical information for both the clinician and the affected individual.

Spectral domain-OCT (SD-OCT) is useful during therapeutic trials to measure macular thickness and the presence of cystoid macular edema [Genead & Fishman 2011].
